Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc. (INBX), bought 10,000 shares at $98.87 ($999K) on 2026-09-25, disclosed to the SEC on 2026-09-28.
CEO Mark Lappe purchased 3,324 shares for $328,630, marking the largest purchase of his career and signaling confidence in the company's oncology pipeline. This buy comes as the stock has corrected significantly from its recent highs, presenting a potential entry point for investors.
The stock is down 11.29% over the last 5 days and 19.58% over the last 30 days, trading at $99.67, which is 35.14% below its 52-week high of $153.68.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $98.87 | 3,324 | $329K | 32.9% |
| 2 | $99.60 | 2,176 | $217K | 21.7% |
| 3 | $98.88 | 1,500 | $148K | 14.9% |
| 4 | $101.70 | 3,000 | $305K | 30.5% |
| Total | $99.88 avg | 10,000 | $999K | 100% |